A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase
2 dose (RP2D) of SNDX-5613 in patients with acute leukemia.
In Phase 2, patients will be enrolled in 3 indication-specific expansion cohorts to determine
the efficacy, short- and long-term safety, and tolerability of SNDX-5613.